Shared on01 Aug 25Fair value Increased 17%
The consensus analyst price target for Aurinia Pharmaceuticals has increased to $11.57, reflecting heightened investor optimism as evidenced by a higher future P/E ratio, despite a modest decline in net profit margin. What's in the News Aurinia Pharmaceuticals raised its 2025 total revenue guidance to $260–$270 million and net product sales guidance to $250–$260 million.